(Q33366516)

26 July 2017

1 reference

title

Direct thrombin inhibitors: pharmacology and clinical relevance (English)

1 reference

26 July 2017

1 reference

P C A Kam

1

1 reference

26 July 2017

N Kaur

series ordinal

2

1 reference

26 July 2017

C L Thong

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

60

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

565-574

1 reference

Emerging anticoagulant drugs

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Coronary Plaque Disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

The dynamics of thrombin formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Current anticoagulant therapy--unmet clinical needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Tissue factor and tissue factor pathway inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

A novel approach to thrombin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Direct thrombin inhibitors in acute coronary syndromes: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Low-molecular-weight heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

The evolving role of direct thrombin inhibitors in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

The emerging role of low-molecular-weight heparin in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

A player of many parts: the spotlight falls on thrombin's structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Design and Study of Piracetam-like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

History of drugs for thrombotic disease. Discovery, development, and directions for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Historical perspective of the development of thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Recombinant hirudin in clinical practice: focus on lepirudin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Clinical results with direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Bivalirudin: a new approach to anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An In Vitro Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Clinical pharmacology of bivalirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Oral direct thrombin inhibitors in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Ximelagatran: a new oral anticoagulant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Characterization of in Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Current and future challenges of antithrombotic agents and anticoagulants: Strategies for reversal of hemorrhagic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Recombinant factor VIIa as an antidote for anticoagulant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Current concepts of hemostasis: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Anticoagulation of patients with heparin-induced thrombocytopenia in cardiac surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Heparin-induced thrombocytopenia and cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

Argatroban anticoagulation in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2044.2005.04192.X

10.1111/J.1365-2044.2005.04192.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference